Get the Stockscreener App
3.28
3.14%
0.10
After Hours:
3.34
0.06
+1.83%
Sana Biotechnology Inc stock is traded at $3.28, with a volume of 3.58M.
It is up +3.14% in the last 24 hours and down -4.09% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
See More
Previous Close:
$3.18
Open:
$3.23
24h Volume:
3.58M
Relative Volume:
0.99
Market Cap:
$912.80M
Revenue:
-
Net Income/Loss:
$-241.99M
P/E Ratio:
-3.4934
EPS:
-0.9389
Net Cash Flow:
$-133.64M
1W Performance:
+4.46%
1M Performance:
-4.09%
6M Performance:
-34.00%
1Y Performance:
-33.74%
1-Day Range:
$3.23
$3.465
1-Week Range:
$3.05
$3.465
52-Week Range:
$2.61
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.28 | 884.97M | 0 | -241.99M | -133.64M | -0.9389 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Wedbush | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Mar-18-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
Sana Biotechnology Inc (SANA) Valuation: PE, PB & Fair Value Analysis - TradingKey
SANA|Sana Biotechnology Inc|Price:3.285|Chg%:+0.105 - TradingKey
Sana Biotechnology Inc (SANA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Sana Biotechnology Inc (SANA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TradingKey - TradingKey
Sana Biotechnology Inc (SANA) Institutional Confidence - TradingKey
Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold (NASDAQ:SANA) - Seeking Alpha
Sana Biotechnology Inc (SANA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sana Biotechnology, Inc. Revenue Breakdown – NASDAQ:SANA - TradingView
SANA|Sana Biotechnology Inc|Price:3.190|Chg%:-0.020 - TradingKey
Sana Biotechnology Inc (SANA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SANA|Sana Biotechnology Inc|Price:3.215|Chg%:+0.095 - TradingKey
Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation - Seeking Alpha
Sana Biotechnology (SANA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Sana Biotechnology (SANA) Experiences Modest Decline as Stock Nears Support ZoneGolden Cross - dars.gov.et
Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM - Yahoo Finance
Sana Biotechnology (SANA) Edges Lower Amid Biotech Sector Volatility; Key Support Levels in FocusTick Index - dars.gov.et
Sana Biotechnology - Nasdaq
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 D - The Manila Times
Sana Biotechnology Announces Follow-On Publication in The - GlobeNewswire
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Ko - The National Law Review
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA)Contact Levi & Korsinsky Before May 20, 2025 - The National Law Review
Sana Biotechnology (SANA) Is Up 18.1% After Removal From Key Russell Value IndexesWhat's Changed - simplywall.st
Sana Biotech heads to EASD with diabetes cell therapy update - Longevity.Technology
Sana Biotechnology (SANA) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr
Sana Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Bishop Hans Edgar - Moomoo
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
Form 4 Sana Biotechnology Inc For: 7 July By Investing.com - Investing.com Nigeria
Sana Biotechnology (SANA) director Hans Bishop receives 6,297 vested RSU shares - Stock Titan
Sana Biotechnology (SANA) Surges Over 12% as Bulls Test Key ResistanceCombination Correction - dars.gov.et
SANA Should I Buy - Intellectia AI
SANA BIOTECHNOLOGY INC (SANA) Stock Chart - ChartMill
Will Removal From Russell Value Benchmarks Change Sana Biotechnology's (SANA) Institutional Investor Narrative? - Sahm
Sana Biotechnology (SANA) Proxy filing Summary - Quartr
Sana Biotechnology (SANA) Q1 2026 earnings summary - Quartr
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 - The Manila Times
Sana Biotechnology Announces Symposium Presentation at the - GlobeNewswire
Citizens reiterates Sana Biotechnology stock rating on IND filing By Investing.com - Investing.com Canada
Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 3000E Value Benchmark - marketscreener.com
Sana Biotechnology, Inc.(NasdaqGS: SANA) dropped from Russell 2500 Value Benchmark - marketscreener.com
Join Class Action to Recover Losses from Sana Biotechnology, Inc - The National Law Review
Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025 - The National Law Review
Enterprise value to EBIT forward of Sana Biotechnology, Inc. – NASDAQ:SANA - TradingView
Price to earnings forward of Sana Biotechnology, Inc. – NASDAQ:SANA - TradingView
Price to book forward of Sana Biotechnology, Inc. – NASDAQ:SANA - TradingView
Sana Biotechnology, Inc. Actuals & Estimates (NASDAQ:SANA) - TradingView
SANA Forecast — Price Target — Prediction for 2027 - TradingView
Sana Biotechnology (SANA) Edges Higher, Holds Above SupportActive ETF Flow - dars.gov.et
SANA News | SANA BIOTECHNOLOGY INC (NASDAQ:SANA) - ChartMill
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):